Sponsored by
The Musella Foundation gave the researchers a grant about 9 years ago for the early work on this new drug! They have trials for newly diagnosed glioblastoma and recurrent high grade glioma, and this new study is trying an oral form of the drug (it is also being used IV). There is also an expanded access program for H3K27 mutant diffuse midline glioma including DIPG.